Are Accelerometer-based Functional Outcome Assessments Feasible and Valid After Treatment for Lower Extremity Sarcomas? by Furtado S et al.
 1 
 
The feasibility and validity of accelerometer-based physical functioning measurement after 
treatment for musculoskeletal tumors of the lower extremity. 
Sherron Furtado1, Alan Godfrey2, Silvia Del Din3, Lynn Rochester3,4, Craig Gerrand5 
INSTITUTIONS:  
1. North of England Bone and Soft Tissue Tumor Service, Department of Orthopaedics, 
Freeman Hospital, Newcastle Upon Tyne, United Kingdom, NE77DN. 
2. Computer and Information Science Department, Northumbria University, Newcastle Upon 
Tyne, United Kingdom, NE1 8ST. 
3. Institute of Neuroscience/Newcastle University Institute for Ageing, Clinical Aging 
Research Unit, Campus for Ageing and Vitality, Newcastle University, NE4 5PL.  
4. Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK 
5. The London Sarcoma Service, Royal National Orthopaedic Hospital NHS Trust, Stanmore, 
UK 
Academic degrees and email id of Authors: 
• Dr Sherron Furtado – PhD, MSc Physiotherapy, B.P.Th. sherron.furtado@newcastle.ac.uk 
• Dr Alan Godfrey - PhD (Bio-medical Electronics). alan.godfrey@northumbria.ac.uk 
• Dr Silvia Del Din – PhD (Bioengineering). Silvia.Del-Din@newcastle.ac.uk 
• Professor Lynn Rochester – PhD. lynn.rochester@newcastle.ac.uk 
• Mr Craig Gerrand - MBChB, FRCSEd (Trauma and Orthopaedics), MD, MBA 
craig.gerrand@nhs.net 
Corresponding Author: Dr Sherron Furtado: sherron.furtado@newcastle.ac.uk 
Contact number: + 44 (0) 191-22-31514 
Contact Address: Room 22a, Level 1, Freeman Hospital, Newcastle Upon Tyne, NE7 7DN. 
Running title: Objective balance and gait assessment after sarcoma treatment 
Keywords: Balance, gait, functional outcomes, musculoskeletal tumors, sarcoma. 
Declaration of Interest: CG and SF report securing grants from Children with Cancer UK Charity, Sarcoma 
UK Charity, Shear’s Foundation and Research and Capability (RCF) funding to the institution during the 
conduct of the study. Funders: This work and SF were supported by above grants. AG and LR were 
supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre 
(BRC) and Unit (BRU) based at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle 
University. The work of AG, SDD and LR was also supported by the NIHR Newcastle Clinical Research 
Faculty infrastructure funding at the time of the project co-ordination. The views expressed are solely those 
of the authors.  
Ethical Review Committee Statement (Attachment) and Statement of Location: This work was 
undertaken at the major clinic sites and Human Movement Room at the North of England Bone and Soft 
Tissue Tumor Service, Newcastle Upon Tyne Hospitals NHS Foundation Trust, UK. 
 2 
 
Abstract 
Background: Aspects of physical functioning including balance and gait are affected after 
surgery for lower limb musculoskeletal tumors. These are not routinely measured, but small 
inexpensive portable accelerometers could evaluate these in a clinically useful manner. 
Research Question: Are accelerometer-based body worn monitor (BWM) assessments of 
balance, gait and timed up and go tests (TUG) feasible, acceptable and valid in patients treated 
for lower extremity musculoskeletal tumors? 
Methods: This was a prospective cross-sectional study. Patients performed standard activities 
whilst wearing a BWM (Axivity, AX3) on the lower back, including standing, walking and TUG 
tests. Summary measures of balance (area (ellipsis), magnitude (RMS), jerkiness (jerk), 
frequency (f95) of postural sway), gait (temporal outcomes, step length and velocity) and TUG 
time were derived. BWM outcomes in patients were compared to control groups, routine clinical 
scales (MSTS, TESS, QoL) and standard manual techniques (video and stopwatch) to assess 
discriminant, convergent and concurrent validity respectively. 
Results: 34 patients were treated for tumors in the femur (19), pelvis/hip (3), tibia (9), or ankle/foot 
(3). 27 had limb sparing surgery and 7 amputation. BWM assessments were well tolerated, feasible 
to perform and produced clinically useful data. Balance and gait measures distinguished patients 
and controls (discriminant validity). BWM assessments correlated with existing clinical scales 
(convergent validity) and manual techniques (concurrent validity) (p<0.05).  
Conclusion: BWMs can quantify physical functioning in patients treated for lower extremity 
tumors, are acceptable and valid. Balance and gait relate to disability and QoL. These 
measurements can provide important information to guide rehabilitation strategies. 
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1. Introduction 
Major surgery, chemotherapy and radiotherapy for musculoskeletal tumors in the pelvis and 
lower extremity have a detrimental impact on the locomotor system [4]. The impaired balance 
and gait that result [7, 9] often lead to reduced mobility, lack of confidence, loss of adaptive 
mechanisms to maintain the body in space, and falls [41, 54]. Despite this, balance and gait 
assessments are not part of routine clinical practice [16].  
Balance and gait can be clinically assessed by visual examination or patient-completed scales [17, 
49]. However, these methods are subjective, may not detect subtle abnormalities and measures 
have ceiling effects [21]. Furthermore, difficulties in interpreting results can complicate the 
delivery of rehabilitation [21]. Objective functional assessments are therefore advocated after 
sarcoma treatment [16]. Simple tests of balance, gait or other composite measures e.g. timed up 
and go (TUG) may reflect objective physical capability and falls risk [26, 33, 53]. 
Despite this, there remains a deficit of valid and reliable objective balance and gait assessments 
for these patients [16]. A low-cost accelerometer-based body worn monitor (BWM) can provide 
valid objective data on balance and gait in healthy individuals and other patient cohorts [11] [20, 
23, 39]. BWMs are sensitive to test conditions [35], demonstrate test-retest reliability [37] and are 
responsive to change [24]. BWMs also promote the harmonisation of data collection (the bringing 
together of different outcomes), provide detailed clinical information and are sensitive to mild 
disability [24]. For instance, BWMs can detect mild balance differences between patients and 
controls in diabetic neuropathy [51] and untreated Parkinsonism [33]. Hence these might be 
particularly useful in patients treated for a musculoskeletal tumor with mild abnormalities of 
function.   
The aim of this study was therefore to investigate whether a simple BWM assessment of balance, 
gait and TUG outcomes in patients treated for lower extremity bone or soft tissue tumors could 
provide useful information to guide treatment, was feasible and valid. The specific aims were to 
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assess their ability to provide clinically useful information (face validity), their acceptability 
(feasibility), compare with healthy controls (discriminant validity), existing clinical measures 
(convergent validity) and with standard manual techniques in clinic (concurrent validity) [48]. 
2. Materials and Methods 
2.1 Participants 
A convenience sample of 34 adults (age: ≥18 years) were recruited from the North of England 
Bone and Soft Tissue Tumor Service (located in Newcastle Upon Tyne Hospitals NHS 
Foundation Trust). Patients were included if they had undergone treatment including surgery 
and/or radiotherapy for a lower extremity bone or soft tissue tumor (iliac crest or below). Patients 
were excluded if undergoing active treatment, had benign bone or soft tissue tumors, were unable 
to take part because of cognitive or physical incapacity or refused to participate. All patients 
provided written informed consent. The study was approved by the National Research Ethics 
committee (NREC) (Reference: 13/NE/0296) and the Newcastle Upon Tyne Hospitals NHS 
Foundation Trust, Research and Development department (Reference: 6801). The study was 
conducted according to Ethical Standards of Helsinki declaration and Good clinical practice 
(GCP) guidelines. Healthy controls from other parallel studies (NREC: 12/NE/0319 and NREC: 
09-H0906-82/ 08-H0906-147) provided age-matched references for comparison [29, 58]). The 
protocols for BWM assessment in patients and controls were identical. 
2.2 Demographics and clinical measures 
Demographics and clinical characteristics including diagnosis, treatments and time since surgery 
were collected. Patients completed established measures of disability (Toronto Extremity Salvage 
Score, TESS), impairment (Musculoskeletal Tumor Rating System, MSTS), and quality of life 
(Quality of life-Cancer survivors (QoL-CS)) (Table 1).  Homogenous clinical groups were 
constituted, comprising those with similar types of tumor (bone tumour (BT) or soft tissue 
sarcoma (STS)), surgery (limb sparing (LSS) or amputation (AMP)) and anatomical location 
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(above or below knee). The groups were: LSS for above knee BT; LSS for below knee BT; LSS 
for above knee STS ; LSS for below knee STS ; above knee AMP for BT or STS; below knee 
AMP for BT or STS. 
2.3 Equipment 
Participants were asked to wear a tri-axial accelerometer-based BWM (Axivity AX3 dimensions 
23.0, 32.5 and 7.6 mm, weight: 11.0 g, sampling frequency 100Hz, range ± 8 g, Figure 1A) which 
has been validated for human movement analysis  [32]. The sensor was located on the lower back 
(over the 5th lumbar vertebrae) within the pocket of a lumbar belt (Figure 1B). This is close to the 
centre of mass (COM), where readings can quantify a range of physical functioning tasks [19].  
2.4 BWM Protocol and Data collection 
Participants wearing the BWM in the clinic underwent standard tests to assess balance, gait and 
timed up and go (TUG) outcomes (also referred to as BWM outcomes):  
a) Test 1: Standing (balance) test  
Participants were asked to stand upright on a level surface wearing their own footwear, feet 
slightly apart, hands by their side and eyes open  [38] for 120 s [34]. 
b) Test 2: Intermittent fast walk (gait) test  
Three intermittent fast walks were completed in which participants were instructed to walk as fast 
as possible without running along a 7-metre walkway [14]. 
c) Test 3: 7-metre instrumented timed up and go (iTUG) (physical capability) test  
This test involved standing up from a chair, walking for 7 meters at a regular pace, turning 
around, walking back to the chair and sitting down [59], repeated three times. 
Participants completed feedback forms about acceptability, comfort and user-friendliness of 
monitors at the end of the assessment.   
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2.5 Data Processing using established algorithms 
Raw data downloaded from the BWM (using OMGUI 1.0 Configuration and Analysis software) 
were processed using established algorithms [10, 11, 19] (Figure 1C) to derive balance, gait and 
iTUG outcomes using MATLAB® (R2012a) (Supplementary Material).  
a) Algorithm 1# Derivation of balance outcomes 
Raw acceleration signals in the antero-posterior (AP) and medio-lateral (ML) planes were used to 
assess standing balance in these directions [10, 33, 34]. Balance measures derived were; (i) area 
(ellipsis), (ii) magnitude (RMS), (iii) jerk, (iv) frequency (f95) of postural sway (Table 1). 
Balance outcomes were normalised over time (120 s), for comparison with controls.  
b) Algorithm 2# Derivation of gait outcomes 
Initial contact (IC)/final contact (FC) events identified from the vertical acceleration were used to 
extract gait measures : (i) temporal characteristics including step, stride, stance, swing time and 
time to complete a fast walk (total gait time) [36] (ii) spatial characteristics including step length, 
estimated using the inverted pendulum model [60] and (iii) spatio-temporal characteristic step 
velocity calculated as step length/step time.  
c) Algorithm 3# Derivation of  iTUG outcome  
Time taken to complete the 7-metre iTUG time was the primary outcome, estimated from raw 
accelerometer signals using established algorithms [3].  
2.6 Clinical interpretation of normal versus impaired BWM outcomes  
Patients with a high postural sway were classified as impaired [7] and those with lower values as 
unimpaired (Figure 2A, 2B, 2C, 2D). Patients with high temporal values of gait, small step length 
and reduced step velocity were classified as impaired. Low iTUG time indicated better function 
whilst high iTUG time poorer function [59].  
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3. Statistical analysis 
Parametric data were expressed using means and standard deviations (SDs) (min – max) and non-
parametric data using medians with interquartile ranges (IQR). BWM outcomes were compared 
between patients and controls, and tumor sub-groups using Independent t or Mann-Whitney U 
tests (to assess convergent validity).  Pearson and Spearman’s rho correlations were used to 
assess relationships between BWM outcomes and clinic measures (for convergent validity). 
Correlations were classified as strong (-1.0 to -0.5 or 0.5 to 1.0), moderate (-0.5 to -0.3 or 0.3 to 
0.5) or weak (-0.3 to -0.1 or 0.1 to 0.3). Significance was taken at the 0.05 level. ICC agreement 
and Bland Altman analysis tested agreement between BWM measures and standard manual 
techniques (for concurrent validity). ICC agreements were  interpreted as; poor (< 0.5), moderate 
(between 0.5 and 0.75), good (0.75 to 0.9) and excellent ( >0.9) [30, 42].  
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4. Results 
4.1 Demographic and clinical characteristics  
34 adults of mean age 43 ± 20 years participated. Patients were treated for bone (21) or soft tissue 
tumors (13) in the femur (19), pelvis/hip (3), tibia (9), or ankle/foot (3). 27 had limb sparing 
surgery (LSS) and 7 amputation (AMP) and median time from surgery was 79 months (33 – 108) 
(Table 2). Median TESS score was 83.6 (IQR 62.1 – 93.8) (range 8.3 – 100.0), mean MSTS score 
24.5 (SD 7.9) (range 5.0-35.0), median 3-metre TUG time 10.8 seconds (IQR 8.5 – 12.7) (range, 
7.9 to 32.3) s and median QoL-CS total score 7.1 (IQR 6.1 – 7.8) (range 2.7 to 9.1).  
4.2 Feasibility of obtaining BWM outcomes, data loss and acceptability of monitors 
The BWM was feasible to use and quick to set up. Data downloading, processing and derivation 
of outcomes were feasible, taking about 10 minutes. There was minimal data loss: of 34 adult 
assessments, 33 balance, 29 gait and 33 iTUG datasets were available for final analysis. Patients 
found the BWM small and easy to wear. Of 20 participants who returned feedback forms, 19/20 
(95%) found the BWM acceptable and comfortable and 17/20 (85%) found it user-friendly.  
4.3 BWM balance, gait and iTUG outcomes in patients versus healthy controls and tumour 
sub-groups                
There were no significant differences noted for age, BMI and gender distribution between 
patients and healthy controls (p>0.05) (Table 3). Patients demonstrated significant alterations of 
balance and gait compared to controls. 
a) Balance  
Patients had significantly higher ellipsis, RMS and jerk than controls (p<0.05), but no significant 
differences in frequency of sway (p>0.05) (Table 3, Figure 3 A,B).  Sub-group analysis showed 
significantly higher RMS_ML in the ‘LSS for above knee BT’ group (n=11) [0.0017 (0.0013 - 
0.0031) m/s2] than the ‘LSS for above knee BT’ group (n=9) [0.0010 (0.0006 - 0.0015) m/s2] 
[Mann – Whitney U test=21.000, Z= -2.171 p=0.030*). 
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b) Gait  
Patients had  significantly higher step time, stance time, swing time, shorter step length and lower 
step velocity than controls (p<0.05) (Table 3, Figure 4 A, B).  No significant differences were 
noted between tumor sub-groups (p>0.05) (Table 3).  
c) iTUG time 
Patients had a mean iTUG time of 19.49s (16.61 – 24.28). Those in the BT group showed higher 
absolute values for iTUG time [19.82s (16.93 - 24.95)] than STS group [17.97s (15.86 - 24.03)]. 
Patients in the LSS group showed higher absolute values of iTUG time [19.48s (16.45 - 24.37)] 
than the AMP group [19.34s (16.52 - 23.79)].  
4.4 Relationships between BWM balance, gait and iTUG outcomes and existing clinical 
scales 
Strong or moderate negative correlations were observed between MSTS, TESS, QoL-CS and 
postural sway, between MSTS and stance time, swing time and total time and between MSTS, 
TESS and iTUG time (p<0.05) (Table 4). This indicates that more structural impairment is 
associated with impaired balance, gait and reduced physical capability. Furthermore impaired 
balance and reduced physical capability are associated with  higher disability and reduced quality 
of life (QoL).  
4.5 Agreement of BWM measures with manual techniques  
a) Gait (total steps measured by BWM versus Gold standard video) 
ICC showed excellent agreement between techniques (p<0.05) (Table 5). Bland-Altman analysis 
(Figure 5) indicated in five cases, the BWM under-estimated step counts by 2 to 5 steps. 
b) TUG time (Agreement of TUG time measured by BWM versus stopwatch)  
ICC showed excellent agreement between techniques (p<0.05) (Table 6) and Bland-Altman 
analysis (Figure 5) confirmed that in a small number of cases poor agreement was seen, 
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predominantly in elderly patients who used their hands as support during ‘sit to stand’ and ‘stand 
to sit’.   
4.6 Sensitivity of BWM measures 
Sensitive BWM measures with an ability to significantly discriminate between patients and 
healthy controls were ellipsis, RMS, jerk, step time, stance time, swing time, step length, step 
velocity and iTUG time (Table 3). Whereas measures showing significant relationships with 
TESS and QoL were RMS, RMS_AP, total time, step velocity and iTUG time (Table 4).  
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5. Discussion 
This is the first study to our knowledge investigating BWM assessments of balance and gait after 
sarcoma treatments.  
5.1 Feasibility, data loss and acceptability of a BWM in the clinic 
BWMs are feasible and straightforward to use, acceptable and user-friendly for patients. 
Clinically useful outcomes could be obtained promptly, with minimal data loss. 
5.2 BWM outcomes in tumor patients versus controls and across tumor sub-groups 
Patients versus controls 
In our study, patients demonstrated altered balance and gait outcomes compared to healthy 
individuals, agreeing with published studies [7] [2, 8]. Results contraindicated De Visser et al, 
2001; in which no significant differences were detected between patients and controls by the 
force platform, for the standing (balance) test [7]. This could be because our study included 
patients after amputation; additionally, triaxial accelerometers may be more sensitive than force 
platforms[35]. The increased step time, swing time, and reduced step velocity in patients 
compared to controls, also agrees with the literature [2, 8]. However, the higher stance phase and 
shorter step length in our patients compared to controls contrasts with published studies [8, 44]. 
This could be because our study used a combined value including the affected and unaffected 
limbs. Differences in step length in our study may also reflect inclusion of patients with LSS and 
AMP in different anatomical locations, whereas Rompen et al 2002, only included patients with a 
femoral endoprosthesis [44].  
After resection of major bone and soft tissues  for a lower extremity sarcoma, the loss of sensory 
[55], motor [5] and proprioceptive [15] systems may disrupt physiological systems delaying the 
transmission of sensory data to the central nervous system. Therefore an appropriate timely 
response to activate postural muscle groups and maintain balance and posture may not be 
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formulated [25-27]. This might impact gait and performance tests (TUG), explaining a higher 
iTUG time (poor physical capability) in patients [19.486s (16.610 – 24.280) ] compared to 
controls [14.3 ± 0.5 s] [59]. 
Tumor sub-groups 
Although no statistical differences were seen between tumor sub-groups, the general trends 
showing BTs performing worse than STS and AMP performing worse than LSS agrees with the 
literature [1][50] . It also makes clinical sense as treatment of BTs in general requires more 
extensive surgery including bone reconstruction; and after AMP,  major limb loss and disrupted 
sensory and proprioceptive input may lead to poorer function [1][31]. Statistical differences were 
not seen (for RMS_ML) until categorised into homogenous groups, highlighting the importance 
of sub-grouping in this heterogeneous patient group. The ability of BWM measures to distinguish 
between groups confirms discriminant validity for patients vs controls and ‘LSS for above knee 
BT’ versus ‘LSS for above knee STS’ sub-groups. 
5.3 BWM measures against existing clinical measures  
In our study, higher impairments (measured by MSTS) relate to poor balance, gait and TUG 
outcomes. Furthermore poor balance, gait and TUG outcomes relate to greater disability and 
reduced QoL (physical and social components). Relationships between balance and QoL agree 
with findings in other clinical conditions [52] [47]. Therefore simple clinic tests can give an 
indication of patients ‘at risk’ of higher disability and reduced QoL. When these outcomes were 
mapped to International Classification of Functioning, Disability and Health (ICF) framework 
[18], relationships were sensible between BWM measures and existing clinic measures (an 
indicator of convergent validity) and could be vital in informing rehabilitation.  
5.4 Agreement of BWM measures with manual standard techniques in clinic 
BWM measures demonstrated good or excellent agreement with standard techniques, but some 
cases underestimated step counts. These were patients with obvious gait deviations while walking 
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(eg heel drag) or low gait velocity (<1.4 m/s), because of which some steps may not be detected. 
Slower gait speeds are known to cause an underestimate of steps [28, 46]; for which 
synchronisation (communication of data) between devices at the start of assessment might help.  
Although an excellent agreement was observed between devices, stopwatch time was 1.1 s higher 
than iTUG time, possibly due to errors in manual timing [22]. The BWM time starts when the L5 
monitor moves upwards during ‘sit to stand’, whereas the stopwatch runs between the command 
“GO” and “STOP”. Poorest agreement appeared to be for slower patients in whom the stopwatch 
had probably been started before the BWM acceleration threshold was reached. Although this 
initial and final struggle is important to capture, a clear advantage of using a BWM is that a range 
of additional measures of postural transitions and gait could be derived [59].  
Sensitive measures identified (ellipsis, RMS, jerk, step time, stance time, step length, step 
velocity, total gait time, iTUG time) could be useful in specific clinical assessments. Sensitive 
BWM measures satisfy indicators of validity, and allow health care professionals to trust their 
accuracy in clinical practice [43, 48]. 
5.5 Strengths, limitations and future work  
A single BWM can capture multiple attributes of physical functioning quickly, advantageous in 
busy clinics. As BWMs are portable, functional evaluations could also be performed at home, 
reducing travel to specialist centres. This could result in a cost-effective follow-up for identifying 
‘at-risk’ patients. The strengths of the algorithms were that minimal data loss was encountered, 
worked across all age groups and varying functional characteristics [40, 57]. A major weakness 
of the algorithms is that they might not be working effectively for homogenous sub-groups, and 
may require further development. A major limitation of this pilot study is the small sample size 
raising possibility of a Type 2 sampling error. Heterogeneous samples also make it challenging to 
draw robust conclusions due to the risk of investigator and selection bias. A future multi-centre 
collaborative study with higher power with added components of testing reliability of BWM 
 14 
 
measurements and sensitivity to change would be helpful here. Capturing dynamic balance, 
relationships with falls and automating data processing in BWM systems could further promote 
the clinical use of BWMs, which in turn could provide information from BWMs to inform 
improved, objective rehabilitation plans. 
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6. Conclusion 
This pilot study supports the feasibility and validity of an accelerometer-based BWM assessment 
of balance, gait and iTUG outcomes in sarcoma patients. The technique shows promising results 
and offers a cost-effective method for quantifying outcomes, although some further work is 
required. Structural impairments are associated with poor balance, gait and TUG outcomes, 
which in turn are associated with greater disability and reduced QoL. This is vital information 
which can be used to guide rehabilitation strategies.  
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List of Tables 
 Table 1: Existing clinical measures and BWM measures for tumor patients.   
  
S.No Clinic measures Sub-domains Scores 
Existing clinic measures  
1
.
1 
Musculoskeletal Tumor Society 
score (MSTS) version developed in 
1987 (MSTS-1987) for the Lower 
Limb [12] 
7 sub-domains range of motion, 
stability, deformity, pain, muscle 
strength, functional activity and 
emotional  acceptance. 
The MSTS total score is expressed 
from 0-35 (worst to best physical 
functioning). Individual sub-
domain score is 0-5. 
1.  Toronto Extremity Salvage Score 
(TESS) [6] 
30 self-reported items. Scores range from 0 to 100  
(worst to best outcomes). 
3. Quality of Life for Cancer Survivors 
(QoL-CS) [13] 
41-item questionnaire. Scores range from 0 to 100  
(worst to best outcomes). 
4. 3-metre Timed Up and Go (TUG) 
test using stopwatch [56] 
TUG test of 3 metres. Less than 10 s = normal, 10-19 s = 
good mobility, can go out alone, 
mobile without a gait aid, 20-29 s = 
problems, cannot go outside alone, 
requires a gait aid. 
Balance measures  
1. Ellipsis (m2/s4) Area of postural sway during 
standing, including 95 % AP and 
ML direction of the acceleration 
trajectories. 
Large ellipsis compared to healthy 
control data reflects impaired 
balance. 
2. Frequency (Hertz) (f95) Frequency below which 95% of 
power of acceleration power 
spectrum is present. 
Large frequency compared to 
healthy control data reflects 
impaired balance. 
3. Jerk (m2/s5) Rate of change of acceleration 
signals over time, essentially a time 
derivative of acceleration 
Jerk is indicative of control of 
postural sway [10, 33]. 
Large jerk compared to healthy 
control data reflects impaired 
balance. 
4. Root mean square (RMS) (m/s2) Magnitude of acceleration. Large RMS compared to healthy 
control data reflects impaired 
balance. 
Gait measures   
1.  Step time (s) Temporal measure - Step time is 
defined as the time taken to from 
one foot contacting the floor to the 
other foot contacting the floor. 
Higher step time reflects impaired 
gait. 
2.  Stride time (s) Temporal measure - Stride time is 
defined as the time taken to 
complete a stride between two 
successive placements of the same 
foot.  
Higher stride time reflects impaired 
gait. 
3.  Stance time (s) Temporal – Duration of stance phase 
in the gait cycle. 
Higher stance time reflects 
impaired gait. 
4.  Swing time (s) Temporal - Duration of swing phase 
in the gait cycle. 
Higher swing time reflects 
impaired gait. 
5.  Total gait time (s) Temporal - Total time taken to 
complete the intermittent fast walk. 
Higher total gait time reflects 
impaired gait. 
6.  Step length (m) Spatial - Step length is defined as 
the distance covered in an average 
step. 
Lower step length reflects impaired 
gait. 
7.  Step velocity (m/s) Spatio-temporal – Step velocity is 
defined as the rate of change of 
position of a step with respect to 
time. 
Lower step velocity reflects 
impaired gait. 
1.             iTUG time                          Temporal - Duration taken to 
complete the 7-metre TUG test. 
Higher TUG time reflects reduced 
physical capability. 
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Table 2: Demographic and clinical characteristics of participants 
 
Demographic/Clinical factors Patients 
Age  43 ± 20 (range from 19-89) years 
Gender Male 25 (73.5%) 
Female 9 (26.5%) 
Height 1.8±0.10 (1.6 – 1.9) metres 
Weight 78.4 (IQR 66.0 – 101.1) 
( 49.0 to 124.7) kilograms (kgs) 
BMI 25.9 (IQR 21.7 – 31.6),  
[range from 19.2 to 44.1] 
 
 
 
 
 
Type of 
tumor 
Bone tumors 21(61.8%) 
Osteosarcoma 10 (29.4%) 
Ewing’s sarcoma 1 (2.9%)  
Chondrosarcoma 6 (17.6%) 
MFH 2 (5.9%) 
Malignant pilomatrixoma 1 (2.9%) 
Others (Metastatic bone cancer) 1 (2.9%) 
Soft Tissue Sarcoma 13 (38.2%) 
Myxofibrosarcoma 4 (11.8%) 
Synovial Sarcoma  4 (11.8%) 
Others (1 each of leiomyosarcoma, 
myxoid liposarcoma, Primitive 
neuroectodermal tumor (PNET), 
soft tissue chondrosarcoma, and 
soft tissue sarcoma (STS) (high 
grade)) 
5 (14.7%) 
 
Location of 
tumor 
Pelvis/Hip 4 (11.8%) 
Above Knee 18 (52.9%) 
Below knee 9 (26.5%) 
Ankle/Foot 3 (8.8%) 
All LSS patients 27 (79.4%) 
 
Type of LSS 
Excision only 11 (32.4%) 
Excision+Endoprosthesis 12 (35.3%) 
Other LSS (Allograft/Autograft/Flaps) 4 (11.8%) 
All AMP patients 7 (20.6%) 
 
Level of 
surgery 
Pelvis/Hip 7 (20.06%) 
Above Knee 17 (50%) 
Through knee --- 
Below knee 9 (26.5%) 
Ankle/Foot 1(2.9%) 
Number of months post-surgery 79 (33 – 108) months  
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Table 3: BWM outcomes (balance and gait) in tumor patients versus healthy controls, BT vs STS, LSS vs AMP 
 
 
BWM 
measures 
Healthy controls 
(n=22) 
Tumor patients (n=33) p-value 
for 
Patients 
vs 
controls 
(*sig) 
BT group (n=21) STS group (n=12) p-
value 
for BT 
vs 
STS 
(*sig) 
LSS group (n=27) AMP group (n=6) p-
value 
for  
LSS vs 
AMP 
(*sig) 
Median Values  
(25th – 75th 
percentile, 1QR) 
Median Values  
(25th – 75th percentile, 
1QR) 
Median Values  
(25th – 75th 
percentile, IQR) 
Median Values  
(25th – 75th percentile, 
IQR) 
Median Values  
(25th – 75th 
percentile, IQR) 
Median Values  
(25th – 75th 
percentile, IQR) 
Balance measures 
Ellipsis (m2/s4) 0.0007 
( 0.0003 -  0.0502) 
0.0475 
(0.0251 – 0.0810) 
0.001* 0.0461 
(0.0255 - 0.0808) 
0.0503 
(0.0220 - 0.1156) 
0.881 0.0461 
(0.0233 - 0.0879) 
0.0486 
(0.0391 – 0.1936) 
0.455 
RMS 
(m/s2) 
0.0010 
(0.0007 -  0.0042) 
0.0020 
(0.0016 – 0.0036) 
0.009* 0.0021 
(0.0017 - 0.0043) 
0.0018 
(0.0013 - 0.0034) 
0.330 0.0022 
(0.0016 - 0.0048) 
0.0018 
(0.0016 - 0.0022) 
0.362 
RMS_AP (m/s2) 0.0009 
(0.0007 -  0.0051) 
0.0015 
(0.0013 – 0.0029) 
0.034* 0.0016 
(0.0013 - 0.0029) 
0.0014 
(0.0011 - 0.0030) 
0.666 0.0015 
(0.0012 - 0.0034) 
0.0016 
(0.0013 - 0.0019) 
0.779 
RMS _ML 
(m/s2) 
0.0004 
( 0.0002 -  0.0069) 
0.0010 
(0.0007 – 0.0017) 
0.033* 0.0011 
(0.0008 - 0.0018) 
0.0010 
(0.0006 - 0.0018) 
0.329 0.0011 
(0.0007 - 0.0018) 
0.0009 
(0.0006 - 0.0013) 
0.337 
Jerk 
(m2/s5) 
0.0513 
( 0.0371 -  0.0790) 
0.0910 
(0.0493–0.1837) 
0.004* 0.1126 
(0.0575 - 0.2162) 
0.0826 
(0.0406 - 0.1408) 
0.217 0.0870 
(0.0450 - 0.2296) 
0.1222 
(0.0715 - 0.1571) 
0.889 
Jerk_AP (m2/s5) 0.0340 
( 0.0153 -  0.0483) 
0.0423 
( 0.0239 – 0.0723) 
0.073 0.0477 
(0.0254 - 0.0787) 
0.0382 
(0.02338 - 0.0704) 
0.575 0.0423 
(0.0227 - 0.0751) 
0.0427 
(0.0348 - 0.0647) 
0.815 
Jerk_ML (m2/s5) 0.01865 
(0.0163-  0.0285) 
0.5180 
(0.0311–0.1285) 
0.0004* 0.0518 
(0.0323 - 0.1379) 
0.0444 
(0.0261 - 0.1257) 
0.500 0.0518 
(0.0306 - 0.1590) 
0.0499 
(0.0368 –0.1168) 
0.944 
f95_AP 
(Hz) 
1.2125 
(0.7750 -  2.0646) 
1.3500 
( 0.6850 – 2.0650) 
0.686 1.3600 
(0.7250 - 2.0650) 
1.0800 
(0.3150 - 2.1450) 
0.572 1.2900 
(0.6400 - 1.9400) 
1.7200 
(0.6700 - 2.1550) 
0.681 
f95_ML 
(Hz) 
2.6709 
(2.0562 -  2.9167) 
2.6600 
(2.1950 – 3.0350) 
0.698 2.660 
(2.3600 - 3.0350) 
2.6500 
(1.3750 - 3.1100) 
0.697           2.6200 
  (2.0800 - 2.9850) 
2.8300 
(2.2600 -3.0800) 
0.579 
Gait measures  
Step time (s) 0.483 
( 0.451-  0.512) 
0.541 
(0.496 - 0.573) 
<0.001* 0.546 
(0.495 - 0.582) 
0.541 
(0.494 - 0.572) 
0.964 0.540 
(0.497 - 0.572) 
0.564 
(0.481 - 0.635) 
0.628 
Stride time (s) --- 1.063 
(0.986– 1.141) 
--- 1.062 
(0.983 - 1.163) 
1.073 
(0.982 - 1.133) 
0.928 1.060 
(0.990 - 1.133) 
1.109 
(0.952 - 1.263) 
0.686 
Stance time(s) 0.630 
(0.576-0.672) 
0.680 
(0.630 – 0.724) 
0.001 * 0.679 
(0.627 - 0.732) 
0.695 
(0.630 - 0.721) 
0.946 0.677 
(0.630 - 0.712) 
0.704 
(0.617 - 0.803) 
0.628 
Swing time (s) 0.328 
( 0.311 -  0.365) 
0.383 
(0.348 – 0.424) 
<0.001* 0.375 
(0.349 - 0.431) 
0.390 
(0.343 - 0.430) 
0.857 0.383 
(0.349 - 0.430) 
0.381 
(0.333 - 0.486) 
0.979 
Total gait time 
(s) 
---- 4.999 
(3.999 – 5.920) 
--- 5.247 
(4.225 - 6.126) 
4.121 
(3.677 - 5.275) 
0.106 4.300 
(3.677 - 5.949) 
5.154 
(4.646 - 5.952) 
0.360 
Step length (m) 0.695+/-0.106 
(0.514 – 0.957) 
0.641+/-0.092 
(0.460 - 0.820) 
0.044* 0.638+/-0.084 
(0.490 - 0.766) 
0.645+/-0.109 
(0.460 - 0.820) 
0.837 0.630+/-0.097 
(0.460 - 0.820) 
0.681+/-0.067 
(0.560 - 0.766) 
0.252 
Step velocity 
(m/s) 
1.468 +/- 0.242 
(1.078 – 2.169) 
1.196+/0.189 
(0.880 -1.539) 
<0.001* 1.187+/-0.172 
(0.913 - 1.448) 
1.210+/-0.221 
(0.880 - 1.539) 
0.766 1.185+/-0.203 
(0.880 - 1.539) 
1.237+/-0.125 
(1.019 - 1.380) 
0.560 
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Table 4: Relationships between BWM balance, gait and iTUG measures and existing measures (using Spearman’s or Pearson’s correlation) 
  
Clinical scales in 
sarcoma 
Balance 
Measures 
Sample 
number 
(n) 
R value p-value  
 
Gait measures Sample 
number 
(n) 
R value p-value  
 
iTUG 
outcome 
Sample 
number 
(n) 
R value p-value  
 
MSTS total 
(impairment)  
Ellipsis (m2/s4) 33 -0.393 0.024* Total gait 
time(s) 
29 -0.424 0.022* iTUG time    33 -0.514 0.002* 
RMS (m/s2) 33 -0.426 0.013* Step velocity 
(m/s) 
29 0.424 0.022* 
f95_AP (Hz) 32 -0.470 0.007* 
TESS (disability) RMS (m/s2) 28 -0.474 0.011*       No significant correlations iTUG time   28 -0.438 0.020* 
RMS_AP 
(m/s2) 
28 -0.435 0.021* 
RMS (m/s2) 33 0.461 0.007* 
QoL-CS total score 
(QoL)  
RMS (m/s2) 28 -0.453 0.015*       No significant correlations iTUG time   28 -0.398 0.036* 
RMS_AP 
(m/s2) 
28 -0.485 0.009* 
QoL-CS Physical 
sub-score 
RMS (m/s2) 28 -0.493 0.008*      No significant correlations iTUG time   28 -0.384 0.044* 
RMS_AP 
(m/s2) 
28 -0.571 0.002* 
QoL-CS Social   
sub-score 
RMS  (m/s2) 28 -0.440 0.019*      No significant correlations iTUG time   28 -0.494 0.008* 
RMS_AP 
(m/s2) 
28 -0.474 0.011* 
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Table 5: ICC agreement for Video step count and BWM step count  
    
Test 
(n=26) 
Mean SD ICC 
Average 
measures  
95% Confidence Interval p-value  
Lower 
bound 
Upper 
bound 
BWM 
step count 
12.73  
(13 steps) 
2.72 
(3 steps) 
 
0.909 
       
    0.713 
 
0.765 
 
p<0.001* 
Video 
step count 
13.58 
(14 steps) 
2.50  
(3 steps) 
Cronbach's Alpha = 0.932. Cronbach’s Alpha Based on Standardized Items = 0.934, p-value –agreement between 
devices (*=statistically significant)  
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type A Intraclass correlation coefficients using an absolute agreement definition. 
 
 
 
Table 6: ICC Agreement for Stopwatch TUG time vs iTUG time   
Test 
(n=33) 
Mean SD ICC 
Average 
measures  
95% Confidence Interval p-value  
Lower bound Upper bound 
iTUG time 
(s) 
21.18 6.23  
0.933  
                 
0.861 
 
0.968 
 
<0.001* 
Stopwatch 
TUG time (s) 
22.28 6.93 
Cronbach's Alpha = 0.939, Cronbach's Alpha Based on Standardized Items = 0.941, p-value – agreement between 
devices (*=statistically significant) 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type A Intraclass correlation coefficients using an absolute agreement definition. 
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List of Figures 
                       
(A)                                                                     (B) 
 
                                                (C) 
 
Figure 1: Body Worn Monitor (BWM) device  
(A): Photograph of BWM device – Axivity AX3, A triaxial accelerometer capturing 
acceleration in vertical (X axis), medio-lateral (Y axis) and anterior-posterior (Z axis) 
directions. (B) BWM on low back at fifth lumbar vertebra, (L5) level for laboratory testing 
(C) Raw acceleration signal obtained from BWM during an activity: Orange lines is the 
acceleration measured in AP direction, yellow lines in ML direction and blue lines in vertical 
direction.   
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(A) 
 
(B)                                                                                                     
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(C) 
 
(D) 
 
Figure 2: Examples of normal balance outcome vs impaired balance outcomes in patients  
(A) Normal ellipsis outcome in a 19 year old male treated with Above Knee LSS (Excision plus 
proximal femoral reconstruction) for a bone tumor in the thigh demonstrates a low ellipsis = 
0.0113 m2/s4 (i.e small area of postural sway). (B) Impaired ellipsis outcome in a 22 year old 
male treated with an Above Knee AMP for a bone tumor in the thigh demonstrates a high 
ellipsis = 0.5890 m2/s4 (i.e large area of postural sway). (C) Normal f95 outcome in a 19 year 
old female in the Above Knee LSS group (Resection of adductor compartment of thigh for a 
soft tissue tumor) demonstrates a low frequency of sway in the ML direction = 1.160 Hz. (D) 
Impaired outcome in a 22 year old male treated with an Above Knee AMP for a bone tumor in 
the thigh demonstrates a high frequency of sway in the ML direction i.e f95_ML = 3.140 Hz. 
 
 24 
 
 
 
(A) 
 
(B) 
Figure 3: Jitter plots to show an increased postural sway in tumor patients compared to 
healthy controls (p<0.05) (A) Significant higher ellipsis in patients compared to heathy 
controls (B) Significant higher jerk in patients compared to healthy controls. 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
E
ll
ip
si
s 
(m
2
/s
4
)
LSS for above knee BT
LSS for below knee BT
LSS for above knee STS
LSS for below knee STS
Above knee AMP
Below knee AMP
Controls Patients
-0.04
0.16
0.36
0.56
0.76
0.96
1.16
1.36
1.56
1.76
J
er
k
 (
m
2
/s
5
)
LSS for above knee BT
LSS for below knee BT
LSS for above knee STS
LSS for below knee STS
Above knee AMP
Below knee AMP
Controls Patients
 25 
 
 
 (A)
(B)  
Figure 4: Jitter plots to show an altered gait in tumor patients compared to healthy 
controls (p<0.05). (A) Significantly higher step time in patients compared to heathy controls 
(B) Significantly lower step velocity in patients compared to heathy controls.  
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(A) 
 
 
(B) 
Figure 5: Bland-Altman Plots for BWM measures versus standard manual techniques 
(A) Video step count vs BWM step count 
(B) Stopwatch TUG time vs iTUG time 
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